On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t cover the full cost of the CGM.
The new program, called Eversense Bridge, charges patients $99 for the Eversense CGM system, in addition to the cost of the sensor placement by their provider. Patients will be able to get their second sensor for the same price, although the price will increase afterward.
“As with any new medical device or drug, we knew it would take some time for insurance companies to add Eversense CGM to their covered diabetes management options,”Mike Gill, VP and general manager for the US region at Senseonics, told MobiHealthNews in an email. “We were pleased to have many insurers cover Eversense from the beginning, but there are many other people that need this technology and are being denied coverage for this revolutionary long-term technology, and we wanted to help them while they await favorable policy decisions from their insurers.”
In order to be enrolled in the program patients must be over 18 years old, have a commercial or private insurance plan that doesn’t cover the full costs of the CGM system, cannot be enrolled in a federally funded insurance program and cannot be a Massachusetts resident.
WHAT'S THE IMPACT
Diabetes is a notoriously difficult condition to manage and affects 30.3 million Americans, according to the American Diabetes Association.
Several companies have been working on CGM systems, with the aim of making care easier for those living with the condition. Dexcom, Abbott and Ascensia have also been working in the CGM space.
“Eversense provides people with diabetes the freedom from self-insertions and has a removable transmitter can be taken off and on for those times they don’t want anything on their body,” Gill wrote. “All glucose readings are sent directly to a smartphone, so no additional receiver is required. The system also has on-body vibe alerts and audible alerts to warn if glucose levels are too high or about to go low, which is especially important during the night.
WHAT'S THE TREND
The Eversense CGM system officially got the FDA nod in July. It was a long time coming, as the company was waiting on clearance for the technology since November 2016.
Recently the company also announced that Eversense would be integrating with Glooko’s diabetes management system.